Sanofi Consumer Healthcare India Limited operates in consumer healthcare products, including over-the-counter medicines and wellness-oriented brands. Its business benefits from India's growing consumer healthcare market and increasing awareness of self-care products. Brand expansion, distribution reach and product innovation provide opportunities. Consumer demand, regulatory requirements, raw-material costs, pricing and competition remain important factors.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROCE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹7,970 cr | ₹950 cr | ₹266 cr | 30.0 | 115.49 | 22.91 | 73.1% | 98.1% | 0.00 | ₹270 cr | 20.6 | 0.50 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 236 | 69 | 29.87 | +13.3% | +6.7% | 29.2% |
| Mar 2026 | 229 | 68 | 29.44 | +35.7% | +32.8% | 29.6% |
| Dec 2025 | 251 | 66 | 28.87 | +50.0% | +47.0% | 26.5% |
| Sep 2025 | 234 | 63 | 27.31 | +39.8% | +46.3% | 26.9% |
| Jun 2025 | 221 | 61 | 26.36 | +109.5% | +34.4% | 27.5% |
| Mar 2025 | 173 | 50 | 21.69 | — | — | 29.0% |
| Dec 2024 | 171 | 44 | 19.25 | — | — | 25.9% |
| Sep 2024 | 160 | 45 | 19.54 | — | — | 28.1% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | ✗ Fail |
| EPS growth accelerating over 3 quarters | ✗ Fail |
| Sales up 25%+, or sales growth accelerating | ✗ Fail |
| Annual EPS up 25%+ in each of the last 2 years | — Not assessable |
| Net margin above the same quarter last year | ✓ Pass |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✗ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✗ 200-day rising for a month ✗ 50-day above the 150- and 200-day ✗ Close above the 50-day ✗ At least 25% above the 52-week low · low 3,465.10 ✗ Within 25% of the 52-week high · high 5,026.80 ✗ RS percentile 70 or more · RS 15 Trend template - the gate, measured: a modest 21-day edge. | 1/8 | 1 of 8 |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 4 - declining | |
| CAN SLIM | ✗ C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✗ N within 15% of the 52-week high · high 5,026.80 ✗ S more volume on up days than down days (50 sessions) · 0.30x ✗ L RS percentile 80 or more · RS 15 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 1/5 | Weak |
| Darvas | ✗ New 52-week high in the last 120 sessions Darvas needs a new 52-week high to start a box. | 10/100 | No box |
| Turtle | ✗ Close above the prior 55-session high · 4,745.00 ✗ Close above the prior 20-session high · 4,081.00 ✓ Close below the prior 20-session low · 3,530.10 Donchian channel breakout - the Turtle traders' entry. | Breakdown | |
| Greenblatt | — Earnings yield (EBITDA / EV) · 4.9% — Return on capital (ROCE) · 98.1% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately. | 80/100 | Strong |
| Graham | ✗ Price at or below the Graham number · Graham number 626.92 ✗ P/E 15 or less · P/E 30.0 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 22.91 ✓ Current ratio 2 or more · 2.03 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 18/100 | Expensive |
| Piotroski | ✓ Profitable (ROA > 0) ✓ Operating cash flow positive ✓ ROA rising ✓ Cash flow above net profit (earnings quality) ✓ Long-term debt / assets falling ✓ Current ratio rising · 3.85 ✓ No new shares issued — Margin rising (net margin) — Asset turnover rising Joseph Piotroski's F-score, FY 2024 -> 2025. | 7/7 | Strong |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SANOFICONR this stock | -14.1 | -23.5 | -26.6 | -26.0 | — | — | 30.0 | 22.91 | 73.1 | 98.1 | — | 0.00 | 20.6 | 7,970 | 950 | 266 | 115.5 | 0.50 |
| SAKAR | -21.8 | +2.7 | +51.5 | +162.7 | +158.4 | +464.3 | 57.0 | 6.33 | 10.0 | 12.9 | — | 0.17 | 30.8 | 2,054 | 272 | 36 | 16.2 | 0.69 |
| KOVAI | -5.6 | -0.9 | +7.0 | +128.0 | +118.8 | +256.0 | 25.5 | 4.87 | 19.4 | — | — | — | — | 6,429 | — | — | 234.2 | — |
| AHCL | +17.8 | +79.8 | +86.2 | +112.4 | — | — | 11.1 | 6.23 | 47.4 | — | — | 0.19 | 30.7 | 1,434 | — | — | 2.4 | 0.44 |
| VIJAYA | -12.2 | +2.5 | +33.7 | +37.9 | +134.0 | +143.8 | 75.1 | 14.71 | 19.7 | 30.3 | — | 0.00 | 39.6 | 14,078 | 857 | 188 | 18.2 | 0.54 |
| ENTERO | -13.2 | +26.4 | +18.2 | +35.9 | — | — | 52.2 | 3.88 | 6.7 | 10.7 | — | 0.34 | 26.4 | 6,545 | 7,128 | 168 | 28.8 | 0.36 |
| AMANTA | -13.3 | -0.0 | +21.9 | +34.8 | — | — | 39.6 | 2.57 | — | — | — | 1.06 | — | — | 291 | 15 | 4.2 | 0.73 |
| YATHARTH | -14.8 | +14.4 | +30.6 | +19.8 | +147.7 | — | 51.6 | 5.18 | 10.0 | 12.4 | — | 0.14 | 30.2 | 9,356 | 1,334 | 174 | 18.8 | 0.88 |
| LALPATHLAB | -2.8 | +8.9 | +30.0 | +18.6 | +47.0 | -0.3 | 56.8 | 12.32 | 21.6 | 29.1 | — | 0.00 | 36.2 | 30,900 | 2,891 | 546 | 32.5 | 0.41 |
| THYROCARE | -15.3 | -15.2 | +19.9 | +13.6 | +151.4 | +22.7 | 42.6 | 12.80 | 28.8 | 37.8 | — | 0.00 | 28.2 | 7,497 | 876 | 176 | 11.1 | 0.47 |
| STARHEALTH | -0.9 | -6.7 | +7.0 | +7.6 | -8.9 | — | 35.7 | 3.15 | 8.9 | — | — | — | — | 31,904 | — | — | 15.3 | 0.41 |